According to the latest news report, a saffron stigma extract from Activ’Inside (Bordeaux, France), called Safr’Inside, has obtained a new patent in the United States. The news was published in the multimedia publishing brand, Nutritional Outlook.
The patent was issued on 28 February this year in the United States and protects the composition and dosage of safranol in the encapsulated saffron extract. Earlier Malaysia, Europe, and South Africa had also issued patents for Activ’Inside’s saffron extract formulation. The encapsulated saffron extract has a very high safranol content of 0.2% as measured by HPLC. Techcare, an encapsulation technology, has been used to prepare the extract. This technology protects the saffron content from undue alterations while preserving its original composition to give a full spectrum output. As a result, the safranal content is high for this product.
Activ’Inside has conducted seven studies, that include ex-vivo, in-vivo, and clinical trials that have shown the potential of Activ’Inside to regulate serotonin levels, which has a great affect on sleep, stress, premenstrual syndrome, menopause, and digestion.
Source: Sebastian Krawiec. Saffron extract from Activ’Inside has obtained U.S. patent. Nutritional Outlook. 9 March, 2023.